Skip to content

Laura Kärtner

13 papers in the library · 934 citations · publishing 2020-2026

Papers

Sort Most recent Most cited

How high ventilation breathwork alters consciousness: Hypoperfusion, network dynamics, and subjective experience.

Progress in neuro-psychopharmacology & biological psychiatry August 1, 2026 Christian N Schmitz, Marijan Bernardic, Anamaria-Domnica Vlădoiu et al.

High ventilation breathwork (HVB) is increasingly used in psychotherapeutic and contemplative contexts to induce altered states of consciousness (ASC), yet its neurobiological mechanisms remain poorly understood. Thirty experienced HVB practitioners (mean age 44.97 ± 11.80 years) underwent perfusion and resting-state fMRI to assess acute cerebrovascular and post-acute network changes. Cerebral...

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Psychotherapy and Psychosomatics May 27, 2026 Lea J. Mertens, Felix Betzler, Manuela Brand et al.

Psilocybin shows promise for treatment-resistant depression (TRD), but long-term data are limited. This study examined the antidepressant effect of one or two psilocybin doses with adjunct psychotherapy in TRD until twelve months. This is a naturalistic follow-up of a phase 2b, randomized, active placebo-controlled trial, where participants were randomized to receive two drug administrations...

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

JAMA Psychiatry March 18, 2026 Lea J. Mertens, Michael Koslowski, Felix Betzler et al. 9 citations

Importance: Psilocybin shows promise in treating depression, although limitations of previous research warrant further research. Objective: To investigate the efficacy and safety of oral psilocybin, 25 mg, with adjunct psychotherapy in treatment-resistant depression (TRD). Design, Setting, and Participants: This was a 2-center, triple-blinded (investigator, participant, rater), phase 2b, active...

[Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment].

Der Nervenarzt March 1, 2025 Moritz Spangemacher, Jonathan R Reinwald, Hana Adolphi et al.

Novel antidepressive substances are challenging the explanations for the mechanisms of action of traditional psychopharmacology. What could be the shared effects of various antidepressants and in this context what role do extrapharmacological factors, such as the body and environment, play? The available literature on clinical and preclinical data for assumed combined active factors of...

Treatment with psychedelics is psychotherapy: beyond reductionism

The Lancet Psychiatry December 12, 2023 Gerhard Gründer, Manuela Brand, Lea J. Mertens et al. 103 citations

Treatment of psychiatric disorders with psychedelic substances represents one of the most promising current treatment approaches in psychiatry. Since its inception in the 1950s, therapy with psychedelics has been conceptualised as psychedelic-assisted psychotherapy-ie, a form of psychotherapy that uses the profound biological effects of this class of substances as a catalyst for changing...

The ego in psychedelic drug action – ego defenses, ego boundaries, and the therapeutic role of regression

Frontiers in Neuroscience October 6, 2023 Tobias Buchborn, Hannes Kettner, Laura Kärtner et al. 21 citations

The ego is one of the most central psychological constructs in psychedelic research and a key factor in psychotherapy, including psychedelic-assisted forms of psychotherapy. Despite its centrality, the ego-construct remains ambiguous in the psychedelic literature. Therefore, we here review the theoretical background of the ego-construct with focus on its psychodynamic conceptualization. We...

Body mass index (BMI) does not predict responses to psilocybin

Journal of Psychopharmacology November 14, 2022 Meg J. Spriggs, Bruna Giribaldi, Taylor Lyons et al. 15 citations

Background: Psilocybin is a serotonin type 2A (5-HT 2A ) receptor agonist and naturally occurring psychedelic. 5-HT 2A receptor density is known to be associated with body mass index (BMI), however, the impact of this on psilocybin therapy has not been explored. While body weight-adjusted dosing is widely used, this imposes a practical and financial strain on the scalability of psychedelic...

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world

Psychopharmacology August 8, 2022 Rosalind Watts, Hannes Kettner, Dana Geerts et al. 159 citations

Abstract Rationale A general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connectedness to self, others and the wider world have been reported by participants in clinical trials of psychedelic therapy. Such accounts have led us to a definition of the psychological construct of ‘connectedness’ as ‘a state of feeling connected to...

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

Frontiers in Pharmacology March 31, 2022 Roberta Murphy, Roberta Murphy, Hannes Kettner et al. 229 citations

Background: Across psychotherapeutic frameworks, the strength of the therapeutic alliance has been found to correlate with treatment outcomes; however, its role has never been formally assessed in a trial of psychedelic-assisted therapy. We aimed to investigate the relationships between therapeutic alliance and rapport, the quality of the acute psychedelic experience and treatment outcomes....

[Are psychedelics fast acting antidepressant agents?].

Der Nervenarzt March 1, 2022 Gerhard Gründer, Manuela Brand, Laura Kärtner et al.

Psychedelics, such as psilocybin represent one of the most promising current therapeutic approaches in psychiatry. Psychedelics seem to have not only potent antidepressant effects. Do they also work particularly quickly, i.e. within one day? The available literature on clinical studies of psychedelics in depressive syndromes is presented both from the period up to the prohibition of these...

Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness.

Front Pharmacol March 25, 2021 Hannes Kettner, Fernando E. Rosas, C. Timmermann et al. 205 citations

Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness.

Self-blinding citizen science to explore psychedelic microdosing.

Elife March 2, 2021 Balázs Szigeti, Laura Kärtner, Allan Blemings et al. 192 citations

Microdosing is the practice of regularly using low doses of psychedelic drugs. Anecdotal reports suggest that microdosing enhances well-being and cognition; however, such accounts are potentially biased by the placebo effect. This study used a 'self-blinding' citizen science initiative, where participants were given online instructions on how to incorporate placebo control into their...

Author response: Self-blinding citizen science to explore psychedelic microdosing

December 11, 2020 Balázs Szigeti, Laura Kärtner, Allan Blemings et al. 1 citation

Article Figures and data Abstract eLife digest Introduction Materials and methods Results Discussion Appendix 1 Data availability References Decision letter Author response Article and author information Metrics Abstract Microdosing is the practice of regularly using low doses of psychedelic drugs. Anecdotal reports suggest that microdosing enhances well-being and cognition; however, such...